Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome.
Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome.
复制标题
静脉内脂质体和反义治疗，用于迫切活动过度和间质性膀胱炎/疼痛膀胱综合征。
DOI：
10.1155/2014/601653
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Yoshimura N
中科院分区：
文献类型：
--
作者：
Tyagi P;Kashyap MP;Kawamorita N;Yoshizawa T;Chancellor M;Yoshimura N
目的.以下综述重点介绍膀胱内给药的最新进展，这为逼尿肌过度活动和间质性膀胱炎/膀胱疼痛综合征（IC/PBS）的治疗带来了额外的好处。结果膀胱内途径是限制极强效药物如DMSO对间质性膀胱炎/膀胱疼痛综合征（IC/PBS）患者和肉毒杆菌毒素对逼尿肌过度活动的作用的优选给药途径。口服治疗难治性或需要减轻常规给药途径所遇到的不良反应的患者也选择该途径。在某些情况下，它的有用性可能受到媒介物（载体）毒性或作用持续时间短的限制。已经在努力通过开发用于膀胱内递送包括反义寡核苷酸的生物技术产品的脂质体平台来克服这些限制。结论.采用前瞻性思维的方法可以实现药物递送系统的进步，以改善膀胱疾病的药物治疗。纳米技术领域的最新发展可以将这种治疗模式从难治性病例的二线治疗带到疾病管理的最前沿。
Purpose. The following review focuses on the recent advancements in intravesical drug delivery, which brings added benefit to the therapy of detrusor overactivity and interstitial cystitis/painful bladder syndrome (IC/PBS). Results. Intravesical route is a preferred route of administration for restricting the action of extremely potent drugs like DMSO for patients of interstitial cystitis/painful bladder syndrome (IC/PBS) and botulinum toxin for detrusor overactivity. Patients who are either refractory to oral treatment or need to mitigate the adverse effects encountered with conventional routes of administration also chose this route. Its usefulness in some cases can be limited by vehicle (carrier) toxicity or short duration of action. Efforts have been underway to overcome these limitations by developing liposome platform for intravesical delivery of biotechnological products including antisense oligonucleotides. Conclusions. Adoption of forward-thinking approaches can achieve advancements in drug delivery systems targeted to future improvement in pharmacotherapy of bladder diseases. Latest developments in the field of nanotechnology can bring this mode of therapy from second line of treatment for refractory cases to the forefront of disease management.